Bendamustine and Rituximab As Salvage Therapy In Patients With Chronic Lymphoproliferative Disorders
- Sponsor
- Gruppo Italiano Studio Linfomi
- Study ID
- NCT01224769
- Status
- Completed
Conditions
- Relapsed or Refractory Chronic Lymphoproliferative Disorders
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- bendamustine +/- rituximab — DRUG
Study Details
This retrospective study collects and evaluates the clinical experience reached in Italy on the use of bendamustine alone or combined with rituximab as treatment of patients with relapsed or refractory chronic lymphoproliferative disorders.
Key Dates
- Start date
- Sep 30, 2005
- Status verified
- Oct 2010
- Primary completion
- Dec 31, 2009
- Completion
- Dec 31, 2009
Study Design
- Enrollment
- 109 participants (actual)
Arms
- Arm: bendamustine +/- rituximab
Primary Outcome Measure
overall response rate [ Time Frame: within 1 month after end of treatment ]